View Document Preview and Link Document Date: 2014-08-12 08:05:41 Open Document File Size: 523,92 KB Share Result on Facebook
Company Multiple Sclerosis Trust / Novartis / / Country United Kingdom / / Event FDA Phase / / Facility Glatiramer Acetate The National Institute / / MedicalCondition fever / demyelinating disease / pain / active disease / MS. Confirmed secondary progressive disease / progressive multifocal leukoencephalopathy / Multiple Sclerosis / Plain Language Summary Multiple Sclerosis / rebound disease / disease / highly active disease / infection / MS / clinically isolated syndrome / / Organization Clinical Excellence / Association of British Neurologists / National Institute for Health and Clinical Excellence / Department of Health / NHS / National Institute for Health / / Position Author / responsible commissioner / / Product TA254 / / ProvinceOrState Mississippi / / PublishedMedium the Multiple Sclerosis Trust guide / / Technology NICE Technology / MRI / GPS / / SocialTag 
Clinical Commissioning Policy: Clinical Commissioning Policy: